Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2020-11-27 AGM Information
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
AGM Information Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly discusses the upcoming "ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE NANOBIOTIX DU 30 NOVEMBRE 2020" (Extraordinary General Meeting of Nanobiotix on November 30, 2020). It details the date, time, location (held behind closed doors due to Covid-19), composition of the meeting bureau, and shareholder rights regarding document consultation. This content directly relates to the formal procedures and announcements surrounding a shareholder meeting, which aligns best with the 'AGM Information' category, even though it is a press release announcing the event rather than the formal AGM presentation itself. Given the focus on the EGM logistics and context, AGM-R is the most appropriate classification over a general Regulatory Filing (RNS). The document length (3237 chars) is short, but it is providing substantive information about the meeting structure, not just announcing that a report is attached.
2020-11-27 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 95% confidence The document is a press release announcing two key regulatory filings related to a planned US Initial Public Offering (IPO) and a concurrent European placement. Specifically, it mentions the filing of a Form F-1 registration statement with the SEC and an amendment to its Universal Registration Document with the AMF. Since the document's primary purpose is to announce the publication/filing of these regulatory documents (Form F-1 and amended Universal Registration Document) rather than being the full report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (6825 chars) is substantial, but the content is focused on announcing the filing status of other documents, aligning best with RPA, which covers announcements regarding the release or publication of company reports.
2020-11-20 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that NANOBIOTIX has filed a registration statement on Form F-1 with the SEC for a proposed initial public offering (IPO) in the United States, along with a concurrent European Private Placement. This activity directly relates to fundraising, financing activities, and changes to the company's capital structure (issuing new shares/ADSs). Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it mentions an SEC filing (Form F-1), the core subject is the offering itself, not the final prospectus or the ongoing regulatory process, making CAP more specific than RNS or RPA.
2020-11-20 English
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. The content explicitly states that the entity Amiral Gestion crossed the 5% threshold of capital and voting rights in NANOBIOTIX on November 10, 2020, detailing the number of shares held (5.45% of capital and 5.25% of voting rights). This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (1209 chars), but the content is the declaration itself, not an announcement of a separate report.
2020-11-17 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 96% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that the FDA has provided 'Safe to Proceed' notifications for two new Phase II clinical trials evaluating the product NBTXR3 in combination with pembrolizumab for head and neck cancer. It details the trial designs, objectives, and patient populations. This type of announcement, detailing clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general press release regarding corporate development. Since it is a detailed announcement of clinical strategy and trial initiation, rather than just a brief financial highlight (ER) or a formal regulatory filing (like 10-K or IR), 'Investor Presentation' (IP) is the most fitting category for detailed strategic updates shared with investors, even if presented as a press release. It is not a formal report (10-K, IR) nor a simple announcement of a report (RPA).
2020-11-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces clinical trial updates (FDA 'Safe to Proceed' notifications for two new Phase II trials evaluating NBTXR3). This format, focusing on immediate, material, non-periodic business news, strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing significant operational and clinical development news, it is not a formal periodic report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). While it contains operational updates, the primary function of a press release announcing key developments is often categorized as an Earnings Release (ER) if it's tied to a reporting cycle, or RNS if it's purely regulatory/operational news. Given the content is a major operational update (FDA clearance for new trials) presented as a press release, it fits best under the general Regulatory Filings (RNS) category, as it is a broad announcement of material information that doesn't fit the specific financial report codes (10-K, IR, ER). However, in many databases, major operational announcements that are not explicitly financial results are often classified as RNS. Since it is a press release announcing clinical progress, RNS is the most appropriate general regulatory/announcement category.
2020-11-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.